Clinical trials: Stage II Pancreatic Cancer
Neuroendocrine Tumor, Islet Cell Tumor
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
The purpose of this study is to decide if a medicine that slows growth of new blood vessels can be give after the embolization procedure to prevent or delay new growth of blood vessels to tumors.
- Trial name
- NCT00434109
- Testing
- Sunitinib malate, Hepatic Artery Embolizations
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Gastrointestinal Cancer, Pancreatic Cancer
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Background: A new cancer therapy takes white blood cells from a person, grows them in a lab, genetically changes them, then gives them back to the person.
- Conditions
- Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer
- Trial name
- NCT03745326
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
This European, prospective, multicentre, double-blind randomised study will evaluate the effect of lanreotide (120 mg every 28 days until disease progression) versus placebo in patients with metastatic/locally advanced…
- Trial name
- REMINET (NCT02288377)
- Testing
- lanreotide
- Where
- 24 sites in Belgium, France and 2 more
- Volunteers
- 53 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Pancreatic Cancer Stage IV
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
The purpose of this study is to see if the combination of nivolumab + cabiralizumab + gemcitabine can give prolonged disease control in patients with advanced pancreatic cancer compared to gemcitabine alone.
- Trial name
- NCT03697564
- Testing
- Gemcitabine, Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Cabiralizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Hitendra Patel
Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
This randomized phase II-R/III trial studies gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in…
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT01013649
- Testing
- 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine
- Where
- 689 sites in United States, Belgium and 2 more
- Volunteers
- 546 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
- Trial name
- NCT00427349
- Testing
- AMG 706, octreotide
- Where
- 112 sites in United States
- Volunteers
- 46 people
- Sponsor
- Eastern Cooperative Oncology Group
Pain, Bladder Cancer
Study of D-Methadone in Patients With Chronic Pain
The purpose of this study is to determine the safest dose of d-methadone that can be given, without causing severe side effects in most patients with chronic pain.
- Conditions
- Pain, Bladder Cancer, Breast Cancer, CNS Cancer
- Trial name
- NCT00588640
- Testing
- d-Methadone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
This phase II trial studies how well metformin hydrochloride, leucovorin calcium, fluorouracil, and oxaliplatin work in treating patients with metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01666730
- Testing
- metformin hydrochloride, oxaliplatin, leucovorin calcium
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Cancer, Adult
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
This was a Phase 1/2 multi-institution prospective open label study in which subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer who previously received treatment with chemotherapy with…
- Trial name
- NCT01834235
- Testing
- Gemcitabine, nab-paclitaxel, NPC-1C
- Where
- 12 sites in United States
- Volunteers
- 81 people
- Sponsor
- Precision Biologics, Inc
Pancreatic Cancer
Vorinostat Plus Radiation Therapy in Pancreatic Cancer
Primary Endpoint: To determine the maximum tolerated dose (MTD) of vorinostat + radiation therapy (RT) in patients with locally advanced pancreatic cancer (LAPC). Secondary Endpoints: 1.
- Trial name
- NCT00831493
- Testing
- Chemoradiation (Radiation Therapy), Vorinostat
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Gastroenteropancreatic Neuroendocrine Tumors
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
The purpose of the study is to evaluate the efficacy and tolerability of the combination of Lanreotide Autogel 120 mg and Temozolomide in patients with progressive gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) graded…
- Trial name
- SONNET (NCT02231762)
- Testing
- Lanreotide Autogel 120 mg, Temozolomide (TMZ)
- Where
- 10 sites in Austria, Germany
- Volunteers
- 57 people
- Sponsor
- Ipsen
Metastatic Pancreatic Cancer
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic cancer compared to historical data.
- Trial name
- NCT00383149
- Testing
- Ixabepilone, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- R-Pharm
Pancreatic Cancer
Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00066677
- Testing
- rhuMAB-VEGF, docetaxel
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fox Chase Cancer Center
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
Drugs used in chemotherapy, such as docetaxel and flavopiridol, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00331682
- Testing
- alvocidib, docetaxel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
This phase II trial studies how well niraparib and dostarlimab work in treating patients with germline or somatic BRCA1/2 and PALB2 mutated pancreatic cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04493060
- Testing
- Dostarlimab, Niraparib
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Pancreatic Cancer
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
The goal of this clinical research study is to learn if the combination of RAD001 and erlotinib hydrochloride can slow the growth of advanced pancreatic cancer. The safety of this drug combination will also be studied.
- Trial name
- NCT00640978
- Testing
- RAD001, Erlotinib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer
This study is designed to establish the safety and efficacy of a combination of Erbitux (cetuximab)/Gemzar (gemcitabine)/radiation in patients with pancreatic cancer.
- Trial name
- NCT00225784
- Testing
- Cetuximab/Gemcitabine, Radiotherapy
- Volunteers
- 37 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Pancreatic Cancer
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
This phase II trial studies the side effects and how well irinotecan hydrochloride, oxaliplatin and cetuximab work in treating patients with unresectable or metastatic pancreatic cancer.
- Trial name
- NCT00871169
- Testing
- Irinotecan, oxaliplatin, and cetuximab
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- New Mexico Cancer Research Alliance
Neuroendocrine Tumors
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
The purpose of this study is to test how safe and effective the combination of RAD001 and erlotinib is in patients with neuroendocrine tumors.
- Trial name
- NCT00843531
- Testing
- RAD001, erlotinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Neoplasms, Pancreatic Neoplasms
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Background: LMB-100 is a man-made protein designed to kill cancer cells. LMB-100 targets a cancer marker called mesothelin. Mesothelin is found on the surface of many different tumors, including pancreatic cancer, but is made by…
- Trial name
- NCT02810418
- Testing
- LMB-100, Nab-Paclitaxel, Mesothelin Expression
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)